Valvular & structural heart diseaseCohort study
Comparison of Early Outcomes Following Transjugular Transcatheter Tricuspid Valve Replacement Between Large vs Small Annulus
- Multicentre cohort study
- 13 centres
Authors' conclusion
LuX-Valve Plus TTVR appears to be safe and effective in TR patients regardless of annular size, but TR reduction was more significant in the SAG, with specific differences in some major adverse events between groups.
Study context
- Population
- Patients with grade ≥3 tricuspid regurgitation (TR) undergoing LuX-Valve Plus transcatheter tricuspid valve replacement (TTVR), 13 centres, May 2022 to March 2024
- Participants
- 159 patients
- Exposure
- Large vs small tricuspid annulus in transjugular TTVR
- Large-annulus group (LAG)n = 42
- Small-annulus group (SAG)n = 117reference
- Outcome
- Early outcomes: device, procedural or intraprocedural success; TR reduction; 30-day primary endpoints or clinical success
Main finding
As reported in the abstract
P = 0.001
Observational data: associations, not effects.
Further findings
TVARC-defined intraprocedural success
P = 0.001
Trial-defined primary endpoint · 30 days
P = 0.936
TRISCEND II-defined primary endpoint · 30 days
P = 1.000
TVARC clinical success · 30 days
P = 0.001
Safety
Severe paravalvular regurgitation · occurred only in the LAG
P = 0.017
New-onset third-degree AV block or pacemaker implantation · exclusive to the SAG
| Outcome | LAG | SAG | P value |
|---|---|---|---|
| Severe bleeding | Not reported in the abstract | 9.4% | P = 0.391 |
Severe bleeding
- Comparable between the groups
Original publication
Summarised from the published abstract; every number is checked against it